Interaction Checker
No Interaction Expected
Dolutegravir/Lamivudine (DTG/3TC)
Levonorgestrel (implant)
Quality of Evidence: Very Low
Summary:
Coadministration of dolutegravir/lamivudine and a levonorgestrel progestogen-only implant has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Levonorgestrel is metabolized by CYP3A4 and is glucuronidated to a minor extent. Dolutegravir is not expected to inhibit or induce CYP450 or UGT enzymes at clinically relevant concentrations. No interaction is expected with lamivudine. No clinically significant interaction was observed when dolutegravir (plus emtricitabine/tenofovir or lamivudine/tenofovir) and levonorgestrel implant were administered in non-pregnant women initiating levonorgestrel (35 living with HIV on dolutegravir-based antiretroviral treatment and 35 HIV-negative, antiretroviral naive women). Levonorgestrel AUC24 week and Cmax were 30% and 71% higher in the dolutegravir group and there was no significant difference in median dolutegravir concentrations before and after levonorgestrel.
Description:
View all available interactions with Dolutegravir/Lamivudine (DTG/3TC) by clicking here.
Copyright © 2026 The University of Liverpool. All rights reserved.